Delivering Fast Whole Genome Sequencing Results with Improved Efficiency

Whole genome sequencing (WGS) is the process of analyzing the complete genetic makeup of an organism. WGS helps us better understand the genetic variants within intronic and exonic regions between organisms. The G4 Sequencing Platform addresses the current limitations of WGS by eliminating batching requirements, generating faster results, and seamlessly integrating into existing next-generation sequencing workflows.

High Quality Whole Genome Sequencing​

The rapid run time, high read accuracy, scalable sequencing capacity, and independent handling of samples in separate flow cell lanes–in combination with the plug-and-play compatibility make G4 well-suited for whole genome experiments.

Key capabilities:

  • Novel Rapid sequencing-by-synthesis (SBS) chemistry and state-of-the-art optics deliver 30x coverage of four human genomes in under 24 hours.
  • Highly accurate whole genome data comparable to leading platforms with single-pass accuracy of ~99.9% and uniform coverage of the high-confidence regions.

G4 Specifications for Whole Genome Sequencing

F2 Flow CellF3 Flow Cell
Paired Reads Delivered / Flow Cell200M400M
Paired Reads Delivered / Run800M1.6B
# Samples / Flow Cell10.51
# Samples / Run124
Price / M Paired Read$4$2.5
Run Time<24 hours<24 hours
Quality>85% bases ≥ Q30>85% bases ≥ Q30

The G4 can process up to 4 flow cells in parallel. Number of reads and sequencing output shown is per flow cell.

1Assumes 2×150 read configuration

Performance Characterization of the G4 for Human Whole Genome Sequencing

The WGS Technical Report highlights the capabilities of the G4 to deliver results faster, more flexible whole genome sequencing results with highly accuracy base calling.

G4 Plug-and-Play Capability

We have partnered with industry-leading library preparation providers and bioinformatic pipelines to ensure the G4 Sequencing Platform seamlessly integrates into existing NGS workflows.

Talk to an expert about Whole Genome Sequencing on the G4 today

Speak to a member of the Singular team to learn more about the available kits and capabilities for whole genome sequencing on the G4.

Download WGS Tech Report

Explore and download the G4 Sequencer’s coverage, quality, accuracy and variant calling performance for Whole Genome Sequencing.

Download Quantabio Transcriptome Application Note

Please take a moment to provide some information prior to downloading the application note.

Download Application Note in Partnership With Claret Bioscience

Please provide your information to download the app note.

Talk to an Expert

Provide your information and a member of the Singular Genomics team will be in contact to schedule a meeting.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note